Since its inception in 2001, GDF has supported and increased access to critical quality-assured TB treatments and diagnostics for 165 countries.
Global Drug Facility Highlights for 2024
Treatments Delivered
- Drug-Susceptible TB
- 2.9 million adult treatment courses
- 300,000 paediatric treatment courses
- Drug-Resistant TB
- 85,000 bedaquiline-based regimens for adults
- 88,000 pretomanid-based regimens for adults
- 1,100 bedaquiline-based regimens for children
- 670 delamanid-based regimens for children
- TB Preventive Treatment
- 1.9 million 3HP regimens for adults
Value of Orders Delivered - $350 million
- $239 million of TB medicines
- $111 million of TB diagnostics and medical devices
Countries that procured using the Global Drug Facility - 126
Savings for country programmes from GDF interventions - $40 million
- Key price reduction: $90 per adult treatment course of bedaquiline - a 54% reduction from August 2023 price
Averted 50 Stockouts of TB medicines in 24 countries
GDF Key Product Deliveries
